In the present study, therefore, we assessed the clinical significance of ZFX expression in a cohort of 290 stage II/II CRC patients, focusing on the role of ZFX in CRC progression and the molecular mechanism underlying its action. Here, ZFX is linked to colorectal carcinoma.